N/A N=32 Non Invasive Ventilation as Airway Clearance in Patients With Cystic Fibrosis
Cystic Fibrosis
Primary: Lung Function: Lung Clearance Index — 9; 9.7 lung clearance index
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=12 Study of Humidified Air to Improve Mucociliary Clearance (MCC) in COPD
COPD
Primary: Mucociliary Clearance Rate - 4 Hours — 47; 56 percent clearance — p=0.11
N/A N=28 ALS and Airway Clearance (ALSAC) Therapy
Amyotrophic Lateral Sclerosis · Respiratory Muscle Weakness
Primary: Respiratory Complications Severity — 8.33; 9.0; 7.8 score on a scale
N/A N=21 Absorptive Clearance in the Cystic Fibrosis Airway
Cystic Fibrosis
Primary: Absorptive Clearance Rate — 42; 32 percentage of DTPA absoprtion per hour
Phase 4 N=50 Airway Clearance for Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation
COPD · Chronic Bronchitis · Emphysema
Primary: The Primary Outcome Measure is the Rate of Exacerbations as Defined Using the Winnipeg Criteria. — 5.5; 4 exacerbations per 12 weeks
N/A N=5 The Use of Airway Clearance Devices in ALS
Amyotrophic Lateral Sclerosis
Primary: Number of Subjects With Improved Respiratory Symptoms as Shown by Chest X-Ray Between Baseline and End of Study — 0; 0 Participants
Phase 2 N=17 Hypertonic Saline and Mucociliary Clearance in Children
Cystic Fibrosis
Primary: Percent Mucociliary Clearance at 60 Minutes — 18.6; 15.4 percentage mucociliary clearance — p=0.62
Phase 1 N=16 Durability of Hypertonic Saline for Enhancing Mucociliary Clearance in Cystic Fibrosis
Cystic Fibrosis
Primary: Change in Average Mucociliary Clearance (0-90 Minutes) at 1 and 4 Hrs Post Dose (MCC4hr - MCCbaseline; MCC1hr - MCCbaseline) — 5.9; 6.7 Absolute % change
Phase 1 N=20 Absorptive Clearance After Inhaled Osmotics in Cystic Fibrosis
Cystic Fibrosis
Primary: Absorptive Clearance Rate After Isotonic Saline Inhalation — 32.0 percent cleared / 80 minutes
Phase 2 N=16 Effect of Lucinactant on Mucus Clearance in Cystic Fibrosis Lung Disease
Cystic Fibrosis
Primary: Change in Mucociliary Clearance — 7.4; 9.5 percent clearance
N/A N=25 Comparison of the Airway Clearance Efficacy of Electro Flo 5000 and the G5 Flimm-Fighter in Patients With CF
Cystic Fibrosis
Primary: Wet Sputum Weight — 5.22; 4.19 gram
N/A N=10 Researching the Effects of Airway Clearance Therapies in Cystic Fibrosis
Cystic Fibrosis · Mucociliary Clearance Defect
Primary: Mucociliary Clearance-274 — 20.3; 16.8; 18.5; 19.1 percent clearance — p=0.615
N/A N=24 Phase I Assessment of Hypertonic Saline in Moderate to Severe Asthmatics
Moderate to Severe Asthma
Primary: Change in MCC From Baseline to 7% Post Hypertonic Saline Inhalation — 29.9 percent clearance — p=<0.001
Phase 4 N=14 Inhaled Mannitol on Mucociliary Clearance in Moderate to Severe Cystic Fibrosis
Cystic Fibrosis
Primary: Average Rate of Mucociliary Clearance (MCC) Over 60 Minutes — 14.8 percent cleared over 60 minutes — p=0.04
N/A N=159 Safety Study of Airway Clearance Techniques in Infants.
Gastro-esophageal Reflux
Primary: Number of Refluxes — 0.48; 1.14; 1.62 number of refluxes
N/A N=164 Soiled Airway Tracheal Intubation and the Effectiveness of Decontamination by Paramedics
Airway Management · Intubation, Intratracheal · Laryngoscopy
Primary: Difference in First-pass Intubation Success Rates Before and After SALAD Training — 44; 74 Participants
N/A N=12 Study to Characterize the Durability of Hypertonic Saline to Enhance Mucociliary Clearance in Healthy Subjects
Healthy Subjects
Primary: Change in Whole Lung Mucociliary Clearance — 0.6; -4.0 % Clearance — p=<.05
N/A N=74 Efficacy Study of a Novel Device to Clean the Endotracheal Tube
Endotracheal Extubation · Airway Obstruction · Airway Control
Primary: Percentage of Occlusion Assessed Using a High Definition Computed Tomography Imaging of the Extubated ETTs — 10.6; 17.7 percentage of occlusion
Phase 4 N=17 Comparison of Airway Clearance Therapy in Cystic Fibrosis Using the Same VEST Therapy Device But With Different Settings
Cystic Fibrosis
Primary: Sputum Wet and Dry Weight — 6.4; 4.8; 0.20; 0.12 grams — p=.02
N/A N=272 Evaluation of the CleanSweep™ Closed Suction System on Length of Mechanical Ventilation and Ventilator-Associated Events
Mechanical Ventilation Complication
Primary: Length of Time on a Mechanical Ventilator — 70.6; 72.2 hours
Phase 1 N=20 Study to Assess the Effect of the New HFA-152a Propellant on Mucociliary Clearance
Mucociliary Clearance
Primary: Mucociliary Clearance Rate -- Right Whole Lung -- Percent Particle Retention at 2 Hours (PPR2) on Day 8 — 0.94; -0.42 percent of particle retention — p=0.442
N/A N=23 Effect of Hypertonic Saline on Mucus Clearance in Children Ages 5-12 With Cystic Fibrosis
Cystic Fibrosis
Primary: Change in Mucociliary Clearance Rate — 2.77; -2.35 percent clearance
Phase 3 N=485 Inhaled Mannitol as a Mucoactive Therapy for Bronchiectasis
Bronchiectasis
Primary: Rate of Graded Pulmonary Exacerbations — 1.95; 2.10; 1.69; 1.84 GPE events per year — p=0.3115
Phase 4 N=12 The Effectiveness of Roflumilast in Improving Mucociliary Clearance in Patients With COPD and Chronic Bronchitis
COPD · Chronic Bronchitis · Emphysema
Primary: Difference in Mucociliary Clearance (MCC) Between Visit 1A and Visit 2A — -1.50; -0.70 percentage difference of MCC
Phase 2 N=18 Nebulized Hypertonic Saline for Mechanically Ventilated Children
Respiratory Failure
Primary: Duration of Mechanical Ventilation — 129.5; 208.1 hours
Phase 2 N=38 Evaluating the Effect of Mucinex 1200mg on Mucociliary and Cough Clearance During an Acute Respiratory Infection
Acute Respiratory Infection
Primary: Percent of Inhaled Radioactive Tracer Particles Cleared From Lungs — 21.4; 23.1 Percentage of inhaled radioactive tracer
Phase 3 N=333 A Clinical Trial to Compare the Efficacy and Safety of 1-week Treatment of Intravenous N-acetylcysteine (NAC) 600 mg Twice Daily, Ambroxol Hydrochloride 30 mg Twice Daily and Placebo as Expectorant Therapies in Adult Chinese Patients With Respiratory Tract Diseases and Abnormal Mucus Secretions
Respiratory Tract Diseases · Abnormal Mucus Secretions
Primary: Change From Baseline to Day 7 of Mean Sputum Viscosity Score of NAC and Placebo — -1.2; -1.0 Score — p=<0.001
Phase 4 N=39 Efficacy of Percussive Ventilation Therapy (MetaNeb ®) Compared With Mucolytic Agents for Atelectasis in the Mechanically Ventilated Pediatric Patient
Atelectasis
Primary: Improvement of Atelectasis — 6; 7; 3; 6 participants
Phase 4 N=15 Electro Flo 5000 and Vest Therapy
Cystic Fibrosis
Primary: Wet Sputum Weight — 3.8; 4.6 grams
N/A N=60 Implemental Flutter Mucus Clearance Devices on Geriatric Lung Function
Pulmonary Disease
Primary: Number of Cases With Fever (Body Temperature Reach 38 Degree Celsius or Higher) — 0; 2 participants